Johnson & Johnson (NYSE:JNJ) Shares Sold by Fmr LLC

FMR LLC decreased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,079,929 shares of the company's stock after selling 2,236,991 shares during the period. FMR LLC owned 0.67% of Johnson & Johnson worth $2,325,479,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Principal Financial Group Inc. grew its holdings in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after buying an additional 329,473 shares in the last quarter. United Bank grew its stake in shares of Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after acquiring an additional 202 shares in the last quarter. EP Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 8.9% during the third quarter. EP Wealth Advisors LLC now owns 544,719 shares of the company's stock valued at $88,277,000 after purchasing an additional 44,526 shares in the last quarter. iA Global Asset Management Inc. boosted its holdings in Johnson & Johnson by 27.2% during the third quarter. iA Global Asset Management Inc. now owns 319,787 shares of the company's stock worth $51,825,000 after purchasing an additional 68,372 shares during the last quarter. Finally, Goldstream Capital Management Ltd bought a new stake in Johnson & Johnson in the 3rd quarter worth about $951,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 1.5 %

Shares of NYSE:JNJ traded down $2.24 during trading on Thursday, hitting $148.73. The company had a trading volume of 7,778,407 shares, compared to its average volume of 7,916,499. The stock has a market cap of $358.42 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a fifty day simple moving average of $159.50 and a two-hundred day simple moving average of $155.37. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $171.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.